Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment

Recurrence Remains a Risk Even for Patients Diagnosed via Screening

Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data

Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question

Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC

Should Biomarkers Be Used in the Clinical Management of ES-SCLC?

FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm

MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination

Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

AEGEAN Shows Benefit with the Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC

World Conference Plenary Addresses Barriers to—and Opportunities for—Lung Cancer Care in Low- to Middle-Income Countries